Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

BACKGROUND: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 50% of patients with rheumatoid arthritis have low or absent CD20 B cell...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet
Autores principales: Humby, Frances, Durez, Patrick, Buch, Maya H, Lewis, Myles J, Rizvi, Hasan, Rivellese, Felice, Nerviani, Alessandra, Giorli, Giovanni, Mahto, Arti, Montecucco, Carlomaurizio, Lauwerys, Bernard, Ng, Nora, Ho, Pauline, Bombardieri, Michele, Romão, Vasco C, Verschueren, Patrick, Kelly, Stephen, Sainaghi, Pier Paolo, Gendi, Nagui, Dasgupta, Bhaskar, Cauli, Alberto, Reynolds, Piero, Cañete, Juan D, Moots, Robert, Taylor, Peter C, Edwards, Christopher J, Isaacs, John, Sasieni, Peter, Choy, Ernest, Pitzalis, Costantino
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2021
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7829614/
https://ncbi.nlm.nih.gov/pubmed/33485455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(20)32341-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares